Early recurrence risk: aromatase inhibitors versus tamoxifen. - Wikidata - awgldk - TriplyDB

Early recurrence risk: aromatase inhibitors versus tamoxifen.

Early recurrence risk: aromatase inhibitors versus tamoxifen.

http://www.wikidata.org/entity/Q37782092

about

Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.Pathways to breast cancer recurrence.Complete response to exemestane in a patient with a desmoid tumor.

P2860

Q34103963-88E84CFE-3C29-4351-90F5-B0A7A5103EA6 Q36702139-27FB9DEF-170E-4CA5-8925-0E0BC6CE3414 Q39627437-EC187565-EB76-4DFC-9556-5DABC456B4B0

P2860

Early recurrence risk: aromatase inhibitors versus tamoxifen.

http://www.wikidata.org/entity/Q37782092

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on August 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Early recurrence risk: aromatase inhibitors versus tamoxifen.

@en

Early recurrence risk: aromatase inhibitors versus tamoxifen.

@nl

type

label

Early recurrence risk: aromatase inhibitors versus tamoxifen.

@en

Early recurrence risk: aromatase inhibitors versus tamoxifen.

@nl

prefLabel

Early recurrence risk: aromatase inhibitors versus tamoxifen.

@en

Early recurrence risk: aromatase inhibitors versus tamoxifen.

@nl

P1433

Q37782092-939C1D1A-D24D-494B-9F37-79A2EDE46A7E

P1476

Q37782092-5BEFB836-645A-43AF-84CE-61AC241CE2B3

P2093

Q37782092-33BD9B15-7FB6-4AA0-A7E3-E10F5801711A

Q37782092-64C67379-C196-45AA-B45A-F6F26CBDE76F

Q37782092-6C5C1F4C-F0B0-4538-8BD8-12ECEB8D60B5

Q37782092-7369D044-B9EF-481E-BE2E-E21903F5DDE2

Q37782092-B9A93584-35D4-4D54-9364-97210015A0A3

P2860

Q37782092-0131358C-3BD5-4185-BA23-A60E5DFE1013

Q37782092-07088723-EB2A-4246-B1D2-5A459BAD24EC

Q37782092-0D48EBFC-1A02-4E01-BC9B-773674B9C0C0

Q37782092-11C2F5CF-A132-46FD-B88C-F8A6D9292919

Q37782092-11F56DA0-8807-495B-B563-07B3E47ECA48

Q37782092-13F2370B-60D3-47F1-BF55-072B242F2DCF

Q37782092-18DFBE1F-7AD7-45DC-A9E4-1075DC57DB36

Q37782092-198C3516-DB4C-4160-ABCF-9D6E0FC068E8

Q37782092-1F31F3EB-C651-4E55-A858-DA5A76BD4722

Q37782092-2616E010-82D1-40FA-B371-BA6E75B446B6

P304

Q37782092-86E4ED75-FE9A-41A9-ADC9-D7AF5EE94FC4

P31

Q37782092-60613A17-078A-4B50-BDE6-309F6B078FB7

P356

Q37782092-F82F4EF1-3258-4A09-B3DB-7540638991CD

P433

Q37782092-8C21F98F-49C3-40DC-865C-24E3B92D68B0

P478

Q37782092-29747385-9138-4E1E-8405-A94FD564A0E3

P50

Q37782092-812FF589-614F-407C-B437-00CA3354071A

P577

Q37782092-DE55FE92-1A68-44CB-80EF-4922F9A2931B

P698

Q37782092-D306FF19-37E0-4068-BA3B-9406AE17D174

P356

P1433

Expert Review of Anticancer Therapy

P1476

Early recurrence risk: aromatase inhibitors versus tamoxifen

@en

P2093

Federica Cuppone

http://www.w3.org/2001/XMLSchema#string

Francesco Cognetti

http://www.w3.org/2001/XMLSchema#string

Michele Milella

http://www.w3.org/2001/XMLSchema#string

Paolo Carlini

http://www.w3.org/2001/XMLSchema#string

Vanja Vaccaro

http://www.w3.org/2001/XMLSchema#string

P2860

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.

Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer

Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial.

Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.

Estimates of the cancer incidence and mortality in Europe in 2006.

Meta-analysis of vascular and neoplastic events associated with tamoxifen

P304

1239-1253

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERA.10.54

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20735310

http://www.w3.org/2001/XMLSchema#string